Home Contact Us 中文 English
Yourlocation:Home >News> Observe and study the clinical efficacy of Doxepin combined with trimebutine maleate in the treatment of irritable bowel syndrome

Observe and study the clinical efficacy of Doxepin combined with trimebutine maleate in the treatment of irritable bowel syndrome

Time:2017/8/4 17:09:13

To observe and study the clinical efficacy of Doxepin combined with trimebutine maleate in the treatment of irritable bowel syndrome.

52 patients with irritable bowel syndrome who were treated in the hospital from February 2014 to April 2015 were selected as the study subjects. They were divided into control group (conventional irritable bowel syndrome group) according to the principle of random distribution. 26 cases and observation group (Doxepin combined with trimebutine maleate group) 26 cases, and then the two groups of patients with mild to moderate and severe treatment of total effective rate, before and after treatment of serum related indicators were compared.

The total effective rates of mild to moderate and severe treatment in the observation group were 100.00% and 92.31%, respectively, which were significantly higher than those in the control group (76.92% and 61.54%). Serum SP, VIP, 5-HT and SS (0.15 ± 0.24) ug / mL, (3.27 ± 0.52) umol / L, (16.31 ± 1.76) ng / mL, (101.57 ± 9.21) pg / dL and (1.42 ± 0.20) ug / mL, ± 0.30) umol / L, (13.22 ± 1.45) ng / mL, (86.76 ± 8.20) pg / dL, all lower than the control group, P <0.05, the difference was statistically significant.

Doxepin combined with trimebutine maleate in the treatment of irritable bowel syndrome, the clinical effect is better for the improvement of all aspects of the disease are more obvious.